Sbm Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 15-05-2024
- Paid Up Capital ₹ 0.10 M
as on 15-05-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.00 M
as on 15-05-2024
- Revenue -15.24%
(FY 2021)
- Profit -13.06%
(FY 2021)
- Ebitda 0.17%
(FY 2021)
- Net Worth 8.05%
(FY 2021)
- Total Assets 10.83%
(FY 2021)
About Sbm Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Ajeet Sharma and Radha Sharma serve as directors at the Company.
- CIN/LLPIN
U24232RJ2006PTC022660
- Company No.
022660
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2006
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sbm Pharmaceuticals Private Limited offer?
Sbm Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antiemetic, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Antacid Drugs, Respiratory System Drugs, Anti Asthma Drug, Dicyclomine Hydrochloride Medicine.
Who are the key members and board of directors at Sbm Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajeet Sharma  | Director | 15-Jun-2006 | Current |
| Radha Sharma | Director | 15-Jun-2006 | Current |
Financial Performance of Sbm Pharmaceuticals.
Sbm Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 15.24% decrease. The company also saw a substantial fall in profitability, with a 13.06% decrease in profit. The company's net worth moved up by a moderate rise of 8.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sbm Pharmaceuticals?
In 2021, Sbm Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 28 Jan 2016 | ₹1.00 M | Open |
How Many Employees Work at Sbm Pharmaceuticals?
Sbm Pharmaceuticals has a workforce of 3 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sbm Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sbm Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
